Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeComparisonsSermorelin vs CJC-1295

Comparison

Sermorelin vs CJC-1295

Two growth-hormone-releasing hormone analogues that look similar on paper but sit on opposite sides of the approval line in Australia.

Updated 1 June 20265 min read
Sermorelin
CJC-1295
Class
GHRH analogue.
Modified GHRH analogue.
Australian status
Prescription pathway exists.
Not ARTG-approved.
Typical access
Doctor + compounding pharmacy.
Mostly unregulated online supply.
Evidence
Established pharmacology; historical use.
Limited human trial evidence.
Oversight
Prescriber-supervised.
Usually none.
Sport
Risk area under anti-doping rules.
Prohibited (WADA).

The bottom line

Both are GHRH analogues, but their regulatory status is very different: sermorelin has a legitimate prescription pathway, while CJC-1295 is not ARTG-approved and is usually sold through unregulated channels.

If a peptide in this class is being considered, the lawful, supervised route is the relevant one — not an online checkout.

More comparisons

Semaglutide vs TirzepatidePeptides vs SARMs
Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026
Comparisons are general education, not a recommendation. Any decision should be made with a registered Australian health practitioner. See also Are peptides legal?

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.